Effect of local intracerebral administration of EMD 57445, a selective σ receptor ligand, on the locomotor activity of the rat

Polish Journal of Pharmacology

Volumn 50, Issue 6, 1998, Pages 399-406

  Skuza, Grazyna ^a   Kolasiewicz, Wacław ^a   Dziedzicka Wasylewska, Marta ^a   Margas, Wojciech ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Receptor rat; D1 , D2 receptor binding; EMD 57445; Intracerebral injections; Locomotor activity

Indexed keywords

5 [4 HYDROXY 4 (1,3 BENZODIOXOL 5 YL)PIPERIDIN 1 YL METHYL] 3 (4 METHOXYPHENYL)OXAZOLIDIN 2 ONE HYDROCHLORIDE; APOMORPHINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; PANAMESINE; SIGMA RECEPTOR LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; FOREBRAIN; INTRACEREBRAL DRUG ADMINISTRATION; LATERAL BRAIN VENTRICLE; LOCOMOTION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; ORAL DRUG ADMINISTRATION; PREFRONTAL CORTEX; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR DENSITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BRAIN; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; OXAZOLES; PIPERIDINES; PROTEIN BINDING; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE; RECEPTORS, SIGMA; VISUAL CORTEX;

EID: 0032449717     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bartoszyk G. D., Bender H. M., Hellmann J., Schnorr C., Seyfried C. A.: EMD 57445: a selective sigma receptor ligand with the profile of an typical neuroleptic. CNS Drug Rev., 1996, 2, 175-194.
2. Bartoszyk G. D., Bender H. M., Heusener A., Schnorr C.: Pharmacology of the potential antipsychotic EMD 57445 in animals and humans. Eur. Neuropsychopharmacol., 1995, 5, 331.
3. Bartoszyk G. D., Greiner H. E., Harting J., Stohrer M., Seyfried C. A.: Pharmacological profile of the atypical neuroleptic drug EMD 57445. Soc. Neurosci. Abstr, 1992, 18, 584.
4. Bastianetto S.,Rouquier L., Perrault G., Sanger D. J.: DTG-induced circling behaviour in rats may involve the interaction between a sites and nigro-striatal dopaminergic pathways. Neuropharmacology, 1995, 34, 281-287.
5. Borison R. L., Diamond B. T., Dren A. T.: Does sigma receptor antagonism predict clinical antipsychotic efficacy? Psychopharmacol. Bull.,1991, 27, 103-106.
6. Chouinard G.,Annable L.: An early phase II clinical trial of BW 234U in the treatment of acute schizophrenia in newly admitted patients. Psychopharmacology, 1984, 84, 282-284.
7. Costall B.,Naylor R. J.: The behavioral effects of dopamine applied intracerebrally to areas of the mesolimbic system. Eur. J. Pharmacol.,1975, 32, 87-92.
8. Dahmen N.,Fischer V., Hödl P., Rujescu D., Reuss S., Bartoszyk G. D., Hiemke C.: Induction of c-fos gene expression by the selective sigma receptor ligand EMD 57445 in rat brain. Eur. Neuropsychopharmacol., 1996, 6, 237-243.
9. Davidson J.,Miller R., Wingfield M., Zung W., Dren A. T.: The first clinical study of BW-234U in schizophrenia. Pharmacol. Bull.,1982, 18, 173-176.
10. Debonnel G., de Montigny C.: Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci.,1996, 58, 721-734.
11. Gewirtz G. R., Gorman J. R., Volavka J., Macaluso J., Gribkoff G., Taylor D. P., Borison R.: BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology, 1994, 10, 37-40.
12. Glowinski J.,Tassin J. P., Thierry A. M.: The mesocorticoprefrontal dopaminergic neurons. Trends Neurosci.,1984, 7, 415-418.
13. 1 receptor agonists. Naunyn-Schmied. Arch. Pharmacol.,1997, 356, 455-461.
14. Guy W.,Manov G., Wilson W. H., Ban T. A., Fjetland O. K., Mandberg P. J., Drew A. T.: Psychotropic actions of BW 234U in the treatment of inpatient schizophrenics: a dose-range study. Drug Dev. Res.,1983, 3, 245-252.